Urolithin A Value Index 2026
A normalized price-per-500 mg comparison for current Urolithin A products where both dose and price can be verified.
Why the index is deliberately narrow
We only calculate value when a full-size consumer product has both a captured price and verified Urolithin A dose. Marketplace products with missing prices, samples, dose options and raw-ingredient benchmarks are excluded. That prevents tidy but meaningless math.
Current value comparison
| Product | Price | UA serving | Cost / 500 mg | Value | Transparency |
|---|---|---|---|---|---|
| Double Wood — Urolithin A | $39.95 | 500 mg | $39.95 | 10.0/10 | 7/10 |
| Naturecan — Urolithin A | $40.49 | 500 mg | $40.49 | 9.9/10 | 9/10 |
| ProHealth Longevity — Full Spectrum Urolithin A | $79.95 | 500 mg | $79.95 | 5.3/10 | 10/10 |
| Timeline — Mitopure Softgels | $99.00 | 500 mg | $99.00 | 3.0/10 | 8/10 |
| Timeline — Mitopure Powder | $99.00 | 500 mg | $99.00 | 3.0/10 | 8/10 |
| Timeline — Mitopure Gummies | $99.00 | 500 mg | $99.00 | 3.0/10 | 8/10 |
How to use the score
Value is one axis. A cheaper 500 mg serving may be attractive, but it does not automatically have the same ingredient identity, testing, certification or finished-product evidence as a more expensive branded product.
What the Value Index measures
The Urolithin A Value Index normalizes cost per 500 mg only for full-size products where both current price and dose are captured.
Why 500 mg is the denominator
Five hundred milligrams is the median verified dose and a common market serving, making it a practical comparison unit.
Why value is not efficacy
A lower cost per 500 mg does not prove stronger biological activity, better testing, or superior clinical outcomes.
Why some products are excluded
Samples, dose options, products without captured prices, and raw-ingredient benchmarks are excluded from the value calculation.
How Mitopure changes the interpretation
A higher cost can reflect branded-ingredient research, certification, and finished-product positioning rather than simply raw Urolithin A quantity.
How testing changes the interpretation
A lower-priced product with limited documentation may be less attractive to a buyer who prioritizes auditability.
How to use the index
Use the Value Index alongside Testing Transparency and Evidence Match rather than as a standalone ranking.
Update policy
Prices and pack sizes change. The index should be refreshed when current manufacturer pricing materially changes.
Update trigger 1
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 2
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 3
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 4
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 5
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 6
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 7
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 8
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 9
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 10
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 11
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 12
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 13
For Urolithin A Value Index 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.